Each filer's latest filing for 04272N102 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Infinitum Asset Management, LLC
13G/A
|
9.9% |
2/17/2026
Event 12/31/2025
|
||
| Infinitum Asset Management, LLC | 9.9% | |||
| Infinitum Partners GP, LLC | 9.9% | |||
| Infinitum Cayman Master, Ltd. | 9.9% | |||
|
Suvretta Capital Management, LLC
13G/A
|
9.9% |
8/13/2025
Event 6/30/2025
|
||
| Suvretta Capital Management, LLC | 9.9% | |||
| Averill Master Fund, Ltd. | 8.7% | |||
| Aaron Cowen | 9.9% | |||
| Hillhouse Investment Management, Ltd. 13G/A | 9.5% |
2/17/2026
Event 12/31/2025
|
||
| BlackRock, Inc. 13G/A | 6.8% |
7/27/2026
Event 6/30/2026
|
||
|
Orbimed Advisors LLC
13D/A
|
5.8% |
10/8/2026
Event 10/6/2026
|
||
| Orbimed Advisors LLC | 5.8% | |||
| OrbiMed Capital GP VIII LLC | 2.9% | |||
| OrbiMed Asia GP IV, L.P. | 2.9% | |||
| OrbiMed Advisors IV Limited | 2.9% | |||
|
FMR LLC
13G/A
|
5.8% |
11/5/2026
Event 9/30/2026
|
||
| FMR LLC | 5.8% | |||
| Abigail P. Johnson | 5.8% | |||
| HBM Healthcare Investments (Cayman) Ltd. 13G | 5.4% |
10/15/2025
Event 10/8/2025
|
||
|
Vivo Opportunity Fund Holdings, L.P.
13G
|
5.0% |
10/13/2026
Event 10/6/2026
|
||
| Vivo Opportunity Fund Holdings, L.P. | 3.1% | |||
| Vivo Opportunity Co-Invest, L.P. | 0.3% | |||
| Vivo Opportunity Co-Invest (Cycle 3), L.P. | 1.6% | |||
| Vivo Opportunity, LLC | 5.0% | |||
| Vivo Opportunity Cayman Fund, L.P. | 0.3% | |||
| Vivo Opportunity Cayman, LLC | 0.3% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
|
Octagon Capital Advisors LP
13G/A
|
4.9% |
11/14/2025
Event 9/30/2025
|
||
| Octagon Capital Advisors LP | 4.9% | |||
| Octagon Investments Master Fund LP | 1.9% | |||
| Octagon Private Opportunities Fund LP | 2.0% | |||
| Octagon Special Opportunities Fund LP - Series 4 | 1.0% | |||
| Ting Jia | 4.9% | |||
| Vanguard Group Inc 13G/A | 4.5% |
1/30/2026
Event 12/31/2025
|
||
|
Sofinnova Venture Partners IX, L.P.
13G/A
|
4.1% |
3/5/2026
Event 12/31/2025
|
||
| Sofinnova Venture Partners XI, L.P. ("SVP XI") | 4.1% | |||
| Sofinnova Management XI, L.P. ("SM XI LP") | 4.1% | |||
| Sofinnova Management XI, L.L.C. ("SM XI LLC") | 4.1% | |||
| Dr. James I. Healy ("Healy") | 4.1% | |||
| Dr. Maha Katabi ("Katabi") | 4.1% | |||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 156 | 50.5 M | $1.53B |
| 2026 Q2 | 159 | 46.1 M | $1.60B |
| 2026 Q1 | 140 | 42.1 M | $969M |
| 2025 Q4 | 124 | 40.1 M | $810M |
| 2025 Q3 | 107 | 38.6 M | $712M |
| 2025 Q2 | 100 | 33.6 M | $732M |
| 2025 Q1 | 84 | 29.1 M | $539M |
| 2024 Q4 | 81 | 28.5 M | $757M |
| 2024 Q3 | 69 | 25.9 M | $612M |
| 2024 Q2 | 55 | 21.7 M | $404M |
| 2024 Q1 | 54 | 21.9 M | $389M |